explore -WSS

explore

author：leisure time 2025-10-01 11:33:57 - browse：8962

Adam's take main illustration — Molly Ferguson/STAT

Roivant Sciences’ Matt Gline might be this year’s best biopharma CEO, and other thoughts about Monday’s blockbuster deal with Roche — like, why the heck did Roivant’s stock trade down?

Gline created $5 billion from $50 million — in less than one year.Regular readers know that every December, I choose a best biopharma CEO. It’s a subjective award, but deal-making acumen, management skills, and delivering shareholder value are important measuring sticks. It’s still too early to call this year’s contest, but Gline is a front-runner.

Last December, Roivant essentially acquired an experimental treatment for inflammatory bowel disease called RVT-3101 from Pfizer for $45 million and then spent another $5 million to position the drug for future Phase 3 studies. Less than a year later, Roivant flipped the drug to Roche for at least $7.1 billion.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Printout prescription drug information shouldn’t go digital

WSS

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

Being 'nonadherent' patient made me a more empathetic doctor

Grandmother of French teen shot dead by police officer pleads with rioters to stop the violence

To bolster infectious disease surveillance, genomics powerhouses team up

Inaction leaves children at risk from dangerous chemotherapy drug

Being 'nonadherent' patient made me a more empathetic doctor

hotspot

explore

Wikipedia

Tori Bowie and the unacceptable rates of Black maternal death

Pumping milk in bathrooms at health conferences is common

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Cardiologists urge adding sexual orientation, gender identity to health records

Activists slam private health insurers over coverage restrictions

Archived: an online chat discussing Ebola, vaccines, and a new epidemic

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

The cancer drug shortage isn’t new — and neither are the solutions

Dog Aging Project founders on what lies ahead after losing funding

knowledge

UpToDate has a racism problem: Dr. Stanley Goldfarb

Head of FDA's diagnostics center, who led through Covid, retires

Medicare bonuses could stop drug shortages under Senate plan

Inaction leaves children at risk from dangerous chemotherapy drug

Prescription digital therapeutics are key to pharma’s future

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

knowledge

leisure time

focus

hotspot